Across TCGA pan-cancer cohorts, GCNT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GCNT1 data layer compared with 26 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GCNT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GCNT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
LUAD, PDAC, and HNSC are the cancer types where GCNT1 mass-spec protein most reproducibly stratifies survival.